ArticleFrontiers in pharmacology2021
Clinical and Microbiological Characterization of Carbapenem-Resistant
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Recurrence, Readmission, and Key Mortality Predictors in Patients with Carbapenem-Resistant Enterobacterales Infections.Diagnostics (Basel, Switzerland) · 2025Article
- Molecular epidemiology and clinical characteristics of carbapenem-resistantMicrobiology spectrum · 2025Article
- Clonal dissemination and persistence of Carbapenem-resistantJAC-antimicrobial resistance · 2025Article
- Carbapenem-resistant Enterobacterales infection and colonization in patients with severe burns: a retrospective cohort study in a single burn center.Antimicrobial resistance and infection control · 2025Article
- An analysis of differences in Carbapenem-resistant Enterobacterales in different regions: a multicenter cross-sectional study.BMC infectious diseases · 2024Article
- Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales.Infectious diseases and therapy · 2023Review
- Clinical and resistance characterization of carbapenem-resistantAnnals of translational medicine · 2022Article
- Molecular Characterization ofMicrobiology spectrum · 2022Article
- Occurrence and Characteristics of Carbapenem-ResistantPathogens (Basel, Switzerland) · 2022Article
- Molecular Epidemiology, Risk Factors and Clinical Outcomes of Carbapenem-NonsusceptiblePathogens (Basel, Switzerland) · 2022Article
- Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-ResistantFrontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.